CRT 2026

Panel Discussion | Devices in Heart Failure

Moderator(s)

• 

  Phillip Adamson, MD

  Chief Medical Officer
  CVRx
  Austin, Texas, United States

  Disclosure(s): Abbott Labs: Stock-publicly held company (excluding mutual/index funds) (Ongoing); CVRx: Employee (Ongoing), Stock-publicly held company (excluding mutual/index funds) (Ongoing)
• 

  William T. Abraham, MD

  Professor of Medicine
  The Ohio State University
  Columbus, Ohio, United States

  Disclosure(s): Abbott: Consulting Fees (e.g., advisory boards) (Ongoing); AquaPass: Consulting Fees (e.g., advisory boards) (Ongoing); Bioventrix: Consulting Fees (e.g., advisory boards) (Ongoing); Cardiac Dimensions: Consulting Fees (e.g., advisory boards) (Ongoing), Stock-privately held company (Ongoing); Cordio Medical: Consulting Fees (e.g., advisory boards) (Ongoing); CVRx: Consulting Fees (e.g., advisory boards) (Ongoing); Impulse Dynamics: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Innoventric: Consulting Fees (e.g., advisory boards) (Ongoing); JNJ V-Wave: Consulting Fees (e.g., advisory boards) (Ongoing); SCPharmaceuticals: Consulting Fees (e.g., advisory boards) (Terminated, October 31, 2025), Stock-publicly held company (excluding mutual/index funds) (Terminated, October 31, 2025); Sensible Medical: Consulting Fees (e.g., advisory boards) (Ongoing); Vectorious Medtech: Consulting Fees (e.g., advisory boards) (Ongoing); WhiteSwell: Consulting Fees (e.g., advisory boards) (Ongoing); Zoll Respicardia: Consulting Fees (e.g., advisory boards) (Ongoing)
• 

  Navin K. Kapur, MD, FSCAI FAHA FACC

  Professor of Medicine
  Tufts Medical Center
  Boston, Massachusetts, United States

  Disclosure information not submitted.
• PL

  Phillip H. Lam, MD

  Advanced Heart Failure Cardiologist
  MedStar Health

  Disclosure information not submitted.

Panel Discussant(s)

• 

  Daniel Burkhoff, MD, PhD

  Director: Heart Failure, Hemodynamics and MCS Research
  Cardiovascular Research Foundation
  New York, New York, United States

  Disclosure information not submitted.
• AD

  Akshay Desai, MD

  Brigham and Women's Hospital

  Disclosure information not submitted.
• 

  Marat Fudim, MD

  Associate Professor
  Duke

  Disclosure information not submitted.
• 

  Zvonimir Krajcer, MD

  PVD program director, Editor-in Chief-THI Journal
  Texas Heart Center for Cardiovascular Care at Texas Heart Institute
  Houston, Texas, United States

  Disclosure(s): Anaxiom Corporation: Consulting Fees (e.g., advisory boards) (Ongoing); Second Heart Assist, Inc.: Stock-privately held company (Ongoing); Taurus Vascular: Consulting Fees (e.g., advisory boards) (Ongoing), Stock-publicly held company (excluding mutual/index funds) (Ongoing)
• 

  JoAnn Lindenfeld, MD

  Director, Heart Failure and Transplantation
  Vanderbilt University
  Nashville, Tennessee, United States

  Disclosure(s): Abbott Labs: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); AbioMed: Consulting Fees (e.g., advisory boards) (Ongoing); Alleviant Medical: Consulting Fees (e.g., advisory boards) (Ongoing); AskBio: Consulting Fees (e.g., advisory boards) (Ongoing); Axon: Consulting Fees (e.g., advisory boards) (Ongoing); Boston Scientific: Consulting Fees (e.g., advisory boards) (Ongoing); Cordio: Consulting Fees (e.g., advisory boards) (Ongoing); CVRx: Consulting Fees (e.g., advisory boards) (Ongoing); Edwards Lifesciences: Consulting Fees (e.g., advisory boards) (Ongoing); Intershunt,: Consulting Fees (e.g., advisory boards) (Ongoing); Kestra: Consulting Fees (e.g., advisory boards) (Ongoing); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing); Merck Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing); OrchestraBiomed: Consulting Fees (e.g., advisory boards) (Ongoing); Vectorious: Consulting Fees (e.g., advisory boards) (Ongoing); Volumetrix: Consulting Fees (e.g., advisory boards) (Ongoing); VWave: Consulting Fees (e.g., advisory boards) (Ongoing); Whiteswell: Consulting Fees (e.g., advisory boards) (Ongoing)
• 

  Stanton J. Rowe, PhD

  CEO
  Nidus Biomedical
  Irvine, California, United States

  Disclosure(s): No financial relationships to disclose
• 

  James Udelson, MD

  Chief, Division of Cardiology
  Tufts Medical Center
  Boston, Massachusetts, United States

  Disclosure(s): Alleviant: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); FIRE1: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Reprieve: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing)
• 

  Sandip Zalawadiya, MD

  Associated Professor of Medicine
  Vanderbilt University Medical Center
  Nashville, Tennessee, United States

  Disclosure(s): Endotronix: Consulting Fees (e.g., advisory boards) (Ongoing); Vectorious Medical: Consulting Fees (e.g., advisory boards) (Ongoing)